

Debora Compare

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5311539/publications.pdf>

Version: 2024-02-01

53
papers

2,321
citations

236925

25
h-index

214800

47
g-index

55
all docs

55
docs citations

55
times ranked

3867
citing authors

#	ARTICLE	IF	CITATIONS
1	Probiotics in Gastrointestinal Diseases: All that Glitters Is Not Gold. <i>Digestive Diseases</i> , 2022, 40, 123-132.	1.9	5
2	Wernicke Encephalopathy in Ulcerative Colitis. <i>Inflammatory Bowel Diseases</i> , 2022, 28, e70-e71.	1.9	0
3	Bone Marrow of Contention: A Rare Case of Recurrent Acute Hepatitis. <i>Digestive Diseases and Sciences</i> , 2021, 66, 408-411.	2.3	0
4	Blinded Oral Challenges with Lactose and Placebo Accurately Diagnose Lactose Intolerance: A Real-Life Study. <i>Nutrients</i> , 2021, 13, 1653.	4.1	2
5	Autoimmune hepatitis following SARS-CoV-2 vaccine: May not be a casualty. <i>Journal of Hepatology</i> , 2021, 75, 728-729.	3.7	72
6	Gut Microbes and Hepatic Encephalopathy: From the Old Concepts to New Perspectives. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 748253.	3.7	11
7	Impact of proton pump inhibitors on cytochrome P450 activity assessed by ¹³ C-aminopyrine breath test in patients with cirrhosis. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 608-615.	3.7	4
8	Editorial: proton pump inhibitor use in cirrhosis—a piece of the puzzle. Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 665-666.	3.7	0
9	Duodenal Metatranscriptomics to Define Human and Microbial Functional Alterations Associated with Severe Obesity: A Pilot Study. <i>Microorganisms</i> , 2020, 8, 1811.	3.6	13
10	Non-bismuth and bismuth quadruple therapies based on previous clarithromycin exposure are as effective and safe in an area of high clarithromycin resistance: A real-life study. <i>Helicobacter</i> , 2020, 25, e12694.	3.5	20
11	Characterization of the Duodenal Mucosal Microbiome in Obese Adult Subjects by 16S rRNA Sequencing. <i>Microorganisms</i> , 2020, 8, 485.	3.6	36
12	ENDOSCOPIC PREDICTORS OF RESPONSE TO OCTREOTIDE THERAPY FOR GASTROINTESTINAL BLEEDING DUE TO SMALL BOWEL ANGIOECTASIAS. , 2020, 52, .		0
13	Invasive pulmonary aspergillosis and pulmonary tuberculosis in a patient treated with infliximab for Crohn's disease. <i>IDCases</i> , 2019, 17, e00537.	0.9	6
14	Gastric Normal Adjacent Mucosa Versus Healthy and Cancer Tissues: Distinctive Transcriptomic Profiles and Biological Features. <i>Cancers</i> , 2019, 11, 1248.	3.7	34
15	Pharmacological treatment of gastrointestinal bleeding due to angiodysplasias: A position paper of the Italian Society of Gastroenterology (SIGE). <i>Digestive and Liver Disease</i> , 2018, 50, 542-548.	0.9	15
16	Appropriateness in prescribing PPIs: A position paper of the Italian Society of Gastroenterology (SIGE) Study section "Digestive Diseases in Primary Care". <i>Digestive and Liver Disease</i> , 2018, 50, 894-902.	0.9	30
17	The gut microbiota: A new potential driving force in liver cirrhosis and hepatocellular carcinoma. <i>United European Gastroenterology Journal</i> , 2017, 5, 944-953.	3.8	55
18	A microbiota-centric view of diseases of the upper gastrointestinal tract. <i>The Lancet Gastroenterology and Hepatology</i> , 2017, 2, 298-312.	8.1	77

#	ARTICLE	IF	CITATIONS
19	Lactobacillus casei DG and its postbiotic reduce the inflammatory mucosal response: an ex-vivo organ culture model of post-infectious irritable bowel syndrome. BMC Gastroenterology, 2017, 17, 53.	2.0	83
20	The Metabolic Role of Gut Microbiota in the Development of Nonalcoholic Fatty Liver Disease and Cardiovascular Disease. International Journal of Molecular Sciences, 2016, 17, 1225.	4.1	50
21	The Gut Bacteria-Driven Obesity Development. Digestive Diseases, 2016, 34, 221-229.	1.9	53
22	The human gastric microbiota: Is it time to rethink the pathogenesis of stomach diseases?. United European Gastroenterology Journal, 2015, 3, 255-260.	3.8	181
23	Quality of bowel cleansing in hospitalized patients undergoing colonoscopy: A multicentre prospective regional study. Digestive and Liver Disease, 2015, 47, 669-674.	0.9	22
24	Lactobacillus paracasei F19 versus placebo for the prevention of proton pump inhibitor-induced bowel symptoms: A randomized clinical trial. Digestive and Liver Disease, 2015, 47, 273-279.	0.9	11
25	The Psyche and Gastric Functions. Digestive Diseases, 2014, 32, 206-212.	1.9	18
26	Long acting release-octreotide as "rescue" therapy to control angiodysplasia bleeding: A retrospective study of 98 cases. Digestive and Liver Disease, 2014, 46, 688-694.	0.9	36
27	Alcoholic disease: Liver and beyond. World Journal of Gastroenterology, 2014, 20, 14652.	3.3	173
28	Screening for and surveillance of gastric cancer. World Journal of Gastroenterology, 2014, 20, 13681.	3.3	18
29	Reply to: "Prediction of liver fibrosis progression by non-invasive tests in chronic hepatitis C: The impact of validation". Journal of Hepatology, 2013, 58, 832.	3.7	0
30	Gastrointestinal sensitivity and gastroesophageal reflux disease. Annals of the New York Academy of Sciences, 2013, 1300, 80-95.	3.8	12
31	Vitamin B12 supplementation improves rates of sustained viral response in patients chronically infected with hepatitis C virus. Gut, 2013, 62, 766-773.	12.1	26
32	Tissue resistance in the normal and diseased esophagus. Annals of the New York Academy of Sciences, 2013, 1300, 200-212.	3.8	5
33	The role of gut microbiota in the pathogenesis and management of allergic diseases. European Review for Medical and Pharmacological Sciences, 2013, 17 Suppl 2, 11-7.	0.7	5
34	Gut-liver axis: The impact of gut microbiota on non alcoholic fatty liver disease. Nutrition, Metabolism and Cardiovascular Diseases, 2012, 22, 471-476.	2.6	358
35	13C-Aminopyrine breath test accurately predicts long-term outcome of chronic hepatitis C. Journal of Hepatology, 2012, 56, 782-787.	3.7	14
36	Efficacy of 5-Day Levofloxacin-Containing Concomitant Therapy in Eradication of Helicobacter pylori Infection. Gastroenterology, 2012, 143, 55-61.e1.	1.3	81

#	ARTICLE	IF	CITATIONS
37	MDR1-P-glycoprotein behaves as an oncofetal protein that promotes cell survival in gastric cancer cells. <i>Laboratory Investigation</i> , 2012, 92, 1407-1418.	3.7	34
38	CD133 and CD44 Cell surface markers do not identify cancer stem cells in primary human gastric tumors. <i>Journal of Cellular Physiology</i> , 2012, 227, 2686-2693.	4.1	59
39	Cancer stem cell hypothesis and gastric carcinogenesis: Experimental evidence and unsolved questions. <i>World Journal of Gastrointestinal Oncology</i> , 2012, 4, 54.	2.0	31
40	Contribution of Gut Microbiota to Colonic and Extracolonic Cancer Development. <i>Digestive Diseases</i> , 2011, 29, 554-561.	1.9	48
41	Effects of long-term PPI treatment on producing bowel symptoms and SIBO. <i>European Journal of Clinical Investigation</i> , 2011, 41, 380-386.	3.4	103
42	Global DNA hypomethylation is an early event in <i>Helicobacter pylori</i> -related gastric carcinogenesis. <i>Journal of Clinical Pathology</i> , 2011, 64, 677-682.	2.0	46
43	Non-Steroidal Anti-Inflammatory Drugs in the Carcinogenesis of the Gastrointestinal Tract. <i>Pharmaceuticals</i> , 2010, 3, 2495-2516.	3.8	8
44	Protective effects of <i>Lactobacillus paracasei</i> F19 in a rat model of oxidative and metabolic hepatic injury. <i>American Journal of Physiology - Renal Physiology</i> , 2010, 299, G669-G676.	3.4	83
45	Risk factors in gastric cancer. <i>European Review for Medical and Pharmacological Sciences</i> , 2010, 14, 302-8.	0.7	135
46	Treatment Options for Uncomplicated Diverticular Disease of the Colon. <i>Journal of Clinical Gastroenterology</i> , 2009, 43, 803-808.	2.2	10
47	Tissue ghrelin level and gastric emptying rate in adult patients with celiac disease. <i>Neurogastroenterology and Motility</i> , 2008, 20, 884-890.	3.0	25
48	Interleukin-13 mucosal production in <i>Helicobacter pylori</i> -related gastric diseases. <i>Digestive and Liver Disease</i> , 2008, 40, 240-247.	0.9	21
49	Epigenetic alterations due to diet and <i>Helicobacter pylori</i> infection in gastric carcinogenesis. <i>Expert Review of Gastroenterology and Hepatology</i> , 2008, 2, 243-248.	3.0	26
50	Is Screening for and Surveillance of Atrophic Gastritis Advisable?. <i>Digestive Diseases</i> , 2007, 25, 214-217.	1.9	3
51	<i>Helicobacter pylori</i> and Epigenetic Mechanisms Underlying Gastric Carcinogenesis. <i>Digestive Diseases</i> , 2007, 25, 225-229.	1.9	43
52	Large Brunner's gland adenoma: Case report and literature review. <i>World Journal of Gastroenterology</i> , 2006, 12, 1966.	3.3	59
53	Diagnostic accuracy of the serum profile of gastric mucosa in relation to histological and morphometric diagnosis of atrophy. <i>Alimentary Pharmacology and Therapeutics</i> , 2005, 22, 1139-1146.	3.7	54